Effect of Rufinamide on Chronic Postthoracotomy Pain Syndrome

Pain Clinical Trial

— RUFPTPS  

Official title:

Effect of Rufinamide on Chronic Postthoracotomy Pain Syndrome. A Prospective, Randomized, Double-blind, Placebo Controlled, Monocenter Study.

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT02095899
• Other study ID #: 2013-253
• Status: Withdrawn
• Phase: Phase 2
• First received: February 14, 2014
• Last updated: July 20, 2015
• Start date: March 2014
• Est. completion date: May 2015

Study information

• Verified date: July 2015
• Source: University of Zurich
• Contact: n/a
• Is FDA regulated: No
• Health authority: Switzerland: Swissmedic
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to test if rufinamide has an effect on chronic neuropathic pain in patients with a post thoracotomy pain syndrome.

Description:

Patients with chronic neuropathic pain after thoracic surgery will be evaluated and treated with oxycodone. Patients with a stable analgesic regimen, not reaching a good pain relief will be randomized to receive Rufinamide (Inovelon)vs. Placebo as an ad-on treatment to oxycodone. Neurophysiological and clinical data will be monitored.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: May 2015
• Est. primary completion date: May 2015
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 75 Years

Eligibility

Inclusion criteria, Run-In Phase:

• Age: 18-75 years

• Weight: 50 - 100kg

• Height: 155 - 195cm

• Sufficient command of German language

• Patient after thoracotomy

• Pain duration of more than 6 month.

• Diagnosis of Neuropathic Pain (DN4 questionnaire)

• Average baseline mean last week pain intensity =5 on NRS (numerical rating scale)

• Signed and dated informed consent

Inclusion criteria, Treatment Phase:

• Stable analgesic regimen for at least 7 days prior to randomisation

• Patients not reaching a NRS = 3 (numeric rating scale) with the baseline individually dose adjusted treatment (oxycodone).

Exclusion criteria:

• Contraindications to the class of drugs under study, e.g. (rufinamide, oxycodone) known hypersensitivity or allergy this class of drugs

• Hypersensitivity to triazole derivates - antifungal drugs including: fluconazole (e.g. Diflucan®), posaconazole (Noxafil®), itraconazole (Sporanox®), voriconazole (Vfend®)

• Lactose intolerance, galactosemia or galactokinase deficiency, glucose-galactose malabsorption

• Use of topical analgesics, or nerve block of the affected or adjacent dermatomes (less than to 2 weeks prior to the therapy onset visit or during the study period)

• Women who are pregnant or breast feeding; intention to become pregnant during the course of the study, lack of safe contraception, defined as: female subjects of childbearing potential, not using and not willing to continue using a medically reliable method of contraception for the entire study duration, such as oral, injectable, or implantable contraceptives, or intrauterine contraceptive devices, or who are not willing or able to use any other second (additional) considered sufficiently reliable by the investigator in individual cases. Female subjects who are surgically sterilized/hysterectomized or post-menopausal for longer than 2 years are not considered as being of child bearing potential

• Other clinically significant concomitant disease states (e.g., renal failure, hepatic dysfunction, severe cardiovascular disease, etc)

• Creatinine clearance = 30 ml/min (estimated from serum creatinine using the Cockcroft
• Gault formula) were excluded

• Known drug (opiate or other) or alcohol abuse

• Contraindication to the use of oxycodone

• Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the subject

• Participation in another study with investigational drugs within the 30 days preceding and during the present study

• Enrollment of the investigators, his/her family members, employees and other dependent persons

• Known neurological disease with peripheral manifestations including neuropathy associated with disease such as diabetes

• Known sensory changes from other medical conditions (e.g. infections affecting the investigation areas, post-herpetic neuralgia)

• Epilepsy

• Abnormal electrocardiogram (especially Familial Short QT syndrome)

• Patient having another pain condition with greater pain intensity

• Repeated thoracic surgeries

• Pneumonectomy or chest wall resection

• Bilateral thoracic surgery

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Pain
• Peripheral Nerve Injuries

Intervention

Drug:
• Rufinamide
2x200mg up to max 2x800mg a day Titration over 20days

Locations

Country	Name	City	State
Switzerland	University Hospital Zurich, Institut of Anaesthesiology	Zurich	ZH

Sponsors (1)

Lead Sponsor	Collaborator
University of Zurich

Country where clinical trial is conducted

Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Area of punctuate hyperalgesia immediately after topical capsaicin.	The primary variable to test is the area of punctuate hyperalgesia after topical capsaicin application in patients treated with rufinamide versus placebo.	2h after capsaicin removal	No